Generated by AI
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders. The company is also advancing additional programs, including TZLS-501, an anti-IL-6R antibody aimed at inflammatory pathways, and Milciclib, an oncology candidate evaluated in solid tumors and related cancer indications. Tiziana Life Sciences uses alternative drug delivery approaches, including nasal, oral, and inhalation routes, to support localized immunotherapy and broaden treatment options across autoimmune, inflammatory, and cancer-related markets.
Website14/15 Conduit Street
London, W1S 2XJ
United Kingdom
The latest articles about TLSA.
2026-11-14. The following slide deck was published by Tiziana Life Sciences Ltd in conjunction with this event.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Summary of Feb 9's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about TLSA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.